Formoterol: Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Formoterol
Therapeutic Class: Bronchodilator
Subclass: Long-acting β2-agonist (LABA)
Speciality: Pulmonology
Schedule (India): Schedule H
Route(s): Inhalation (DPI, MDI, Nebulisation)
Formulations Available in India:
| Formulation | Strength | Pack Details |
| Dry Powder Inhaler (DPI) | 6 mcg/dose | Rotacaps/Capsules for inhalation |
| Dry Powder Inhaler (DPI) | 12 mcg/dose | Rotacaps/Capsules for inhalation |
| Metered Dose Inhaler (MDI) | 6 mcg/actuation | 120/200 doses per canister |
| Metered Dose Inhaler (MDI) | 12 mcg/actuation | 120/200 doses per canister |
| Nebuliser Solution | 20 mcg/2 mL | Single-dose vials (limited availability) |
Fixed-Dose Combinations (FDCs) commonly available:
- Formoterol + Budesonide (DPI/MDI)
- Formoterol + Beclomethasone (MDI)
- Formoterol + Fluticasone (DPI)
- Formoterol + Mometasone (DPI)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
⮞ 1. Bronchial Asthma — Maintenance Therapy (Moderate to Severe Persistent Asthma)
⚠️ CRITICAL: NEVER use formoterol as monotherapy in asthma. MUST always be combined with an inhaled corticosteroid (ICS).
| Parameter | Recommendation |
| Starting dose | 6 mcg twice daily via DPI or MDI (as ICS+LABA FDC) |
| Titration | Increase to 12 mcg twice daily based on symptom control after 1–2 weeks |
| Usual maintenance dose | 6–12 mcg twice daily |
| Maximum dose | 24 mcg/day (12 mcg twice daily) |
Clinical Notes:
- Use only as part of ICS+LABA combination therapy
- Corresponds to GINA Step 3/4 therapy in Indian asthma management protocols
- Rapid onset (within 1–3 minutes) makes it suitable for maintenance and reliever therapy (MART) when combined with ICS
- If using MART strategy: additional doses of ICS-formoterol may be taken as needed (max total 72 mcg formoterol/day including maintenance doses — specialist supervision required)
⮞ 2. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Therapy
| Parameter | Recommendation |
| Starting dose | 12 mcg twice daily via DPI or MDI |
| Titration | Not usually required; assess response after 4 weeks |
| Usual maintenance dose | 12 mcg twice daily |
| Maximum dose | 24 mcg/day |
Clinical Notes:
- May be used as monotherapy in COPD (unlike asthma)
- Combination with ICS or LAMA preferred in moderate-severe COPD with frequent exacerbations
- Assess inhaler technique and adherence at each visit
Secondary Indications — Adults Only (Off-label, if any)
⮞ Exercise-Induced Bronchoconstriction (Prevention) — OFF-LABEL
| Parameter | Details |
| Indication | Prevention of exercise-induced bronchospasm in known asthmatics |
| Dose | 6–12 mcg inhaled 15 minutes before exercise |
| Duration | Single dose pre-exercise; not for daily scheduled prophylaxis |
| Supervision | Specialist only |
| Evidence basis | International guidelines; accepted Indian specialist practice |
Note: Regular daily use for this indication may lead to tolerance; SABA (salbutamol) remains first-line for acute pre-exercise prophylaxis.
⮞ Acute Bronchospasm in COPD (Nebulised Formoterol) — OFF-LABEL
| Parameter | Details |
| Indication | Acute exacerbation of COPD in hospital setting |
| Dose | 20 mcg via nebulisation over 10–15 minutes |
| Frequency | May repeat after 30–60 minutes if needed |
| Supervision | Specialist only; ICU/emergency setting |
| Evidence basis | Limited RCT data; Indian tertiary centre protocols |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
⮞ Moderate to Severe Persistent Asthma (ICS+LABA FDC Only)
⚠️ LABA monotherapy is CONTRAINDICATED in paediatric asthma.
| Age Group | Starting Dose | Usual Maintenance | Maximum Dose |
| 5–11 years | 6 mcg twice daily (ICS+LABA FDC) | 6 mcg twice daily | 12 mcg/day |
| ≥12 years | 6 mcg twice daily | 6–12 mcg twice daily | 24 mcg/day |
Clinical Notes:
- Use only in combination with inhaled corticosteroid
- DPI use requires adequate inspiratory flow; assess technique
- For children <6 years, MDI with spacer may be considered under specialist guidance
- Monitor growth (height) annually in children on long-term ICS+LABA therapy
Safety Monitoring:
- Heart rate and rhythm assessment
- Watch for paradoxical bronchospasm
- Assess inhaler technique at each visit
- Monitor for tremor, nervousness, sleep disturbances
Secondary Indications — Paediatric Doses (Off-label, if any)
⮞ Nebulised Formoterol for Acute Bronchospasm — OFF-LABEL
| Parameter | Details |
| Status | NOT ROUTINELY RECOMMENDED |
| If used | 10–20 mcg nebulised under specialist supervision |
| Setting | Paediatric ICU/emergency only |
| Evidence | Limited paediatric data; extrapolated from adult use |
Statement: Not recommended in children below 5 years of age except under paediatric pulmonologist supervision with documented failure of standard therapy.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| All stages | No dose adjustment required |
Rationale: Formoterol undergoes hepatic metabolism; renal excretion is minimal.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | No dose modification needed; use standard doses with clinical monitoring |
| Severe impairment | Use with caution; limited data available — monitor for systemic adverse effects |
CONTRAINDICATIONS
- Known hypersensitivity to formoterol or any formulation component
- LABA monotherapy in asthma (without concurrent ICS) — associated with increased mortality risk
- Severe or acutely deteriorating asthma (not a rescue medication when used alone)
- Cardiomyopathy with documented arrhythmogenic susceptibility
- Untreated life-threatening arrhythmias
CAUTIONS
- Cardiovascular disease (ischaemic heart disease, arrhythmias, hypertension) — may cause tachycardia, palpitations
- Diabetes mellitus — may elevate blood glucose; monitor glycaemic control
- Hyperthyroidism — augmented sympathomimetic response
- Seizure disorders — may lower seizure threshold
- Hypokalaemia — risk of worsening, especially with concurrent diuretics or corticosteroids
- QT prolongation or concurrent use of QT-prolonging drugs
- Acute exacerbation of asthma/COPD — not a substitute for rescue SABA; ensure adequate controller therapy
PREGNANCY
| Parameter | Details |
| Safety | Limited human data; animal studies suggest caution at high doses |
| Risk | Potential for uterine relaxation (tocolytic effect) at high doses; may delay labour |
| Preferred alternatives | Salbutamol (SABA) for acute relief; ICS remains first-line controller |
| When permissible | Only as part of ICS+LABA FDC when asthma poorly controlled on ICS alone; benefit must outweigh risk |
| Monitoring | Maternal heart rate, blood pressure; fetal heart rate monitoring in third trimester |
LACTATION
| Parameter | Details |
| Compatibility | Likely compatible; expected very low milk transfer |
| Drug levels in milk | Very low (minimal systemic absorption from inhaled route) |
| Preferred alternatives | Salbutamol (more safety data); ICS for maintenance |
| Infant monitoring | Feeding tolerance, irritability, sleep disturbance (rare) |
ELDERLY
| Parameter | Recommendation |
| Starting dose | 6 mcg twice daily (lower end of range) |
| Titration | Slower titration; increase only if needed and tolerated |
| Special risks | Increased susceptibility to tremor, tachycardia, arrhythmias, hypokalaemia |
| Monitoring | Heart rate, blood pressure, serum potassium; ECG if cardiac history |
| Additional considerations | Assess inhaler technique; consider MDI with spacer if coordination issues; review polypharmacy for drug interactions |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Non-selective beta-blockers (propranolol, carvedilol) | Antagonism of bronchodilator effect; may precipitate bronchospasm | Avoid concurrent use; use cardioselective beta-blocker if essential |
| MAO inhibitors | Risk of severe hypertensive crisis and arrhythmias | Avoid use within 14 days of MAOI therapy |
| Tricyclic antidepressants | Potentiation of cardiovascular effects (tachycardia, arrhythmias) | Use with caution; monitor cardiac status |
| QT-prolonging drugs (macrolides, fluoroquinolones, antipsychotics, class III antiarrhythmics) | Additive QT prolongation; risk of torsades de pointes | Avoid combination if possible; ECG monitoring if used together |
| Other long-acting sympathomimetics | Additive cardiovascular toxicity | Avoid duplication of LABA therapy |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Loop diuretics (furosemide), Thiazides | Additive hypokalaemia | Monitor serum potassium; supplement if needed |
| Systemic corticosteroids | Enhanced hypokalaemia risk | Monitor potassium during high-dose steroid courses |
| Theophylline/Aminophylline | Additive bronchodilation but increased ADRs (tremor, tachycardia, hypokalaemia) | Use with caution; consider lower doses |
| Xanthine derivatives | Additive cardiovascular and CNS stimulation | Monitor for toxicity |
| Antidiabetic agents | Possible antagonism due to hyperglycaemic effect of LABA | Monitor blood glucose more frequently |
COMMON ADVERSE EFFECTS
- Tremor (dose-related)
- Palpitations
- Tachycardia
- Headache
- Nervousness/anxiety
- Muscle cramps
- Dry mouth
- Throat irritation or cough (with inhalation)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Paradoxical bronchospasm | Discontinue immediately; administer rescue SABA; do not rechallenge |
| Severe hypokalaemia | Monitor ECG; potassium replacement; can precipitate arrhythmias |
| Cardiac arrhythmias (SVT, VT, AF) | Discontinue; cardiac evaluation; manage arrhythmia appropriately |
| QT prolongation / Torsades de pointes | Discontinue; cardiac monitoring; correct electrolytes |
| Anaphylaxis | Immediate discontinuation; emergency management |
| Asthma-related death (with LABA monotherapy) | NEVER prescribe without ICS in asthma |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | FEV₁/peak flow, heart rate, blood pressure, serum potassium (high-risk patients), ECG (if cardiac history) |
| After initiation | Symptom response at 2–4 weeks; inhaler technique assessment; heart rate |
| Long-term | Asthma control assessment (ACT score); exacerbation frequency; serum potassium if on concurrent steroids/diuretics; growth monitoring (height) in children; annual review of ICS+LABA requirement |
BRANDS AVAILABLE IN INDIA
Plain Formoterol:
| Brand Name | Manufacturer | Formulation |
| Foratec | Cipla | DPI Rotacaps |
| Formoterol | Various | DPI/MDI |
Fixed-Dose Combinations (ICS + Formoterol):
| Brand Name | Composition | Manufacturer |
| Foracort | Budesonide + Formoterol | Cipla |
| Symbicort | Budesonide + Formoterol | AstraZeneca |
| Budamate | Budesonide + Formoterol | Lupin |
| Formonide | Budesonide + Formoterol | Cipla |
| Quibron-F | Beclomethasone + Formoterol | Sun Pharma |
| Flohale-F | Fluticasone + Formoterol | Cipla |
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Plain Formoterol DPI (30 caps) | ₹150–250 |
| Plain Formoterol MDI (120 doses) | ₹200–350 |
| ICS+Formoterol FDC inhaler | ₹180–500 (varies by ICS component and brand) |
| Nebuliser solution (per ampoule) | ₹15–30 (limited availability) |
- ICS+LABA combinations included in NLEM
- Plain formoterol monotherapy NOT on NLEM (appropriately, as monotherapy discouraged in asthma)
- Government supply: ICS+LABA available under national programmes
CLINICAL PEARLS
- Never LABA Alone in Asthma: Formoterol monotherapy in asthma is associated with increased mortality — always prescribe with ICS; most formulations in India are appropriately available as FDCs
- Rapid Onset LABA: Unlike salmeterol, formoterol has rapid onset (1–3 minutes), making it suitable for MART (Maintenance and Reliever Therapy) protocols with budesonide-formoterol combinations
- COPD vs Asthma: LABA monotherapy is acceptable in COPD but NOT in asthma; always confirm diagnosis before prescribing
- Inhaler Technique Critical: Assess and re-educate on proper DPI/MDI technique at every visit — poor technique is a common cause of apparent treatment failure
- Step-Up Therapy: Formoterol-ICS combinations represent Step 3/4 therapy per GINA-adapted Indian guidelines; consider stepping down if well-controlled for ≥3 months
- Hypokalaemia Awareness: In patients on concurrent diuretics or systemic steroids, monitor serum potassium — additive hypokalaemia risk with LABAs
TAGS
formoterol; LABA; bronchodilator; asthma; COPD; ICS-LABA; inhaler; maintenance therapy; pulmonology; NLEM-combination; paediatric-use
VERSION
RxIndia v0.1 — 19 Feb 2026
REFERENCES
- CDSCO approved product information
- Indian Pharmacopoeia / National Formulary of India
- NLEM India
- API Textbook of Medicine
- ICMR Asthma Guidelines
- IAP Guidelines for Childhood Asthma
- AIIMS Drug Formulary
- Indian hospital protocols (PGIMER, AIIMS Delhi)
- GINA Guidelines (supportive reference for stepped care approach)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.